MarketCap
Facebook
X
Telegram
Evoke Pharma Market Cap | EVOK
As of August 23, 2026 Evoke Pharma has a market cap of $ 36.6 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Evoke Pharma
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 187 K | 9.81 M | 20.5 M | 67.5 M | 32.6 M | 46.8 M | 40.7 M | 26.6 M | 20.5 M | 39 M | 24.3 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 67.5 M | 187 K | 29.9 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Drug manufacturers industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
HEXO Corp.
HEXO
|
276 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
22.2 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Cumberland Pharmaceuticals
CPIX
|
84.8 M | $ 7.65 | 2.0 % | $ 114 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
18 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
325 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
1.29 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
101 M | - | - | $ 142 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
717 M | - | - | $ 2.06 B |  France |
 |
Athenex
ATNX
|
11.4 M | - | -23.39 % | $ 1.76 M | USA |
 |
Cronos Group
CRON
|
736 M | $ 3.31 | 2.8 % | $ 1.27 B | Canada |
 |
Harrow Health
HROW
|
1.93 B | $ 40.95 | 1.01 % | $ 1.51 B | USA |
 |
Catalent
CTLT
|
10.9 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
31.8 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
340 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
68.2 M | - | - | $ 28.9 M |  Irlanda |
 |
Evolus
EOLS
|
271 M | $ 8.39 | 0.48 % | $ 541 M | USA |
 |
Jupiter Wellness
JUPW
|
2.36 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
23 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
1.72 M | - | - | $ 193 M | Canada |
 |
Assertio Holdings
ASRT
|
75.4 M | - | - | $ 150 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
18.8 M | - | - | $ 55.5 M | USA |
 |
Radius Health
RDUS
|
393 M | - | - | $ 1.42 B | USA |
 |
PetIQ
PETQ
|
396 B | - | 1.64 % | $ 400 M | USA |
 |
Recro Pharma
REPH
|
133 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
12.8 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
119 M | - | -27.8 % | $ 2.56 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
1.85 M | $ 1.34 | 1.12 % | $ 2.26 M | USA |
 |
Zomedica Corp.
ZOM
|
137 M | - | -0.21 % | $ 98 M | USA |
 |
Tricida
TCDA
|
408 M | - | - | $ 3.25 M | USA |
 |
Veru
VERU
|
84.9 M | $ 2.64 | 2.33 % | $ 38.7 M | USA |
 |
cbdMD
YCBD
|
3.58 M | $ 0.51 | 0.43 % | $ 2.05 M | USA |
 |
Bausch Health Companies
BHC
|
2.03 B | $ 6.44 | 0.22 % | $ 2.39 B | Canada |
 |
Emergent BioSolutions
EBS
|
452 M | $ 5.08 | 5.39 % | $ 272 M | USA |
 |
China Pharma Holdings
CPHI
|
2.75 M | $ 0.98 | 0.93 % | $ 4.21 M |  China |
 |
OrganiGram Holdings
OGI
|
151 M | $ 1.25 | 4.17 % | $ 119 M | Canada |
 |
Perrigo Company plc
PRGO
|
1.96 B | $ 14.25 | 3.98 % | $ 1.97 B | USA |
 |
Rockwell Medical
RMTI
|
33.8 M | $ 8.1 | 6.02 % | $ 291 M | USA |
 |
SCYNEXIS
SCYX
|
37.9 M | $ 5.1 | 0.57 % | $ 255 M | USA |
 |
Solid Biosciences
SLDB
|
623 M | $ 9.3 | 2.2 % | $ 814 M | USA |
 |
TherapeuticsMD
TXMD
|
23 M | $ 2.06 | 0.48 % | $ 23.8 M | USA |
 |
Canopy Growth Corporation
CGC
|
292 M | $ 1.05 | 1.43 % | $ 313 M | Canada |
 |
ProPhase Labs
PRPH
|
131 M | - | - | $ 5.07 M | USA |
 |
Aurora Cannabis
ACB
|
224 M | $ 3.94 | 3.41 % | $ 216 M | Canada |
 |
Relmada Therapeutics
RLMD
|
247 M | $ 4.63 | 0.65 % | $ 183 M | USA |
 |
Organogenesis Holdings
ORGO
|
337 M | $ 1.8 | 0.27 % | $ 228 M | USA |
 |
Pacira BioSciences
PCRX
|
1.17 B | $ 24.67 | 3.52 % | $ 1.1 B | USA |
 |
Sundial Growers
SNDL
|
348 M | $ 1.37 | 3.01 % | $ 354 M | Canada |
 |
Tilray
TLRY
|
3.65 B | $ 4.84 | 3.64 % | $ 4.31 B | Canada |